NYC Health + Hospitals/Woodhull Receives IPRO Quality Award for Eliminating Central Line-Associated Bloodstream Infections
The hospital reduced the use of urinary catheters and central line catheters, which helped it achieve six consecutive quarters without central line-associated bloodstream infections.
NYC Health + Hospitals/Woodhull has received a 2024 IPRO Quality Award for “reducing the use of urinary catheters and central line catheters and achieving six consecutive quarters free of central line-associated bloodstream infections (CLABSIs).” Their website has the news.
Clinical teams from the inpatient medical, surgical, and critical care units were all involved in this endeavor. Each team would daily assess “each case where a central line or urinary catheter was in use and whether an alternative could be used instead, contributing to the prompt removal of these invasive devices as soon as they were no longer clinically required.” These efforts led to “decreased use of central line and urinary catheters, which in turn resulted in an overall reduction of central line-associated infections.”
The IPRO Hospital Quality Improvement Contract (HQIC) is “a federal program focused on improving the quality of care provided to Medicare patients across the United States and funded by the Centers for Medicare & Medicaid (CMS).”
Gregory Calliste, the CEO of NYC Health + Hospitals/Woodhull, recognizes the achievement as “a testament to the hard work and dedication of [the] staff in implementing effective infection prevention measures.”
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.